Renal Mass Biopsy in the Management of Small Renal Masses

Summary Over the past two decades, the presentation of renal cell carcinoma (RCC) has shifted from late-stage, symptomatic disease to the incidental detection of small renal masses (SRMs) through widespread ultrasonography and cross-sectional imaging. SRMs, defined as enhancing renal tumors ≤4 cm, represent a heterogeneous spectrum of benign and malignant histologies, with up to 20–30% proving benign on final pathology. This raises concerns about overtreatment, particularly as stage migration has not translated into improved overall survival. Preoperative imaging, though central to evaluation, often cannot reliably distinguish benign from malignant lesions, particularly lipid-poor angiomyolipomas and oncocytomas. Renal mass biopsy (RMB) provides histologic confirmation before intervention, guiding decisions in indeterminate cases. Indications include avoiding unnecessary surgery, pre-ablation confirmation, and tailoring active surveillance strategies; however, RMB should be avoided when its findings will not alter management, such as in clearly resectable tumors planned for surgery. RMB demonstrates >99% accuracy for malignancy detection, high histologic concordance, and low complication rates. In contemporary practice, RMB becomes more than a diagnostic step—it becomes a deliberate conversation, a needle guided not only by imaging, but by insight, tracing the contours of both tumor biology and the patient’s story.